Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
/PRNewswire/ -- Servier, groupe pharmaceutique international indépendant gouverné par une fondation, a annoncé aujourd'hui avoir finalisé l'acquisition de
EWTX - Edgewise Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.09
DETAILS
HIGH:
$66.00
LOW:
$25.00
MEDIAN:
$52.00
CONSENSUS:
$49.09
UPSIDE:
20.20%
Stock News
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval — BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity — — Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential Approval — — On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026 — BOULDER, Colo., June 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET.
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – – CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in Q2 2026 – – Pivotal GRAND CANYON results for sevasemten in Becker expected in Q4 2026 – BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on April 30, 2026, Edgewise granted inducement stock options to purchase a total of 266,000 shares of Edgewise's common stock to 9 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)
ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Edgewise Therapeutics (NASDAQ: EWTX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Valuation and Earnings This table compares ABVC BioPharma
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High – Should You Buy?
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesday. The stock traded as high as $34.00 and last traded at $32.83, with a volume of 577238 shares traded. The stock had previously closed at $33.33. Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation
SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX
SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 797.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,723 shares of the company's stock after acquiring an additional 78,842 shares during the period.
Edgewise Therapeutics (NASDAQ:EWTX) CMO Joanne Donovan Sells 28,662 Shares
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $32.31, for a total value of $926,069.22. The sale was disclosed in a document filed with the Securities and
Price Targets
Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
$55.00
(was $39.46)
Cory Kasimov
·
Evercore ISI
Edgewise Therapeutics initiated with an Outperform at Oppenheimer
$51.00
(was $46.30)
Oppenheimer
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
$51.00
(was $39.83)
Debjit Chattopadhyay
·
Guggenheim
Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital
$59.00
(was $34.51)
RBC Capital
Edgewise Therapeutics (EWTX) PT Raised to $32 at Goldman Sachs
$32.00
(was $33.95)
Paul Choi
·
Goldman Sachs
Edgewise Therapeutics price target raised to $52 from $50 at Leerink
$52.00
(was $33.28)
Leerink Partners
Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright
$45.00
(was $37.57)
H.C. Wainwright
Edgewise Therapeutics (EWTX) PT Lowered to $48 at RBC Capital
$48.00
(was $38.27)
Leonid Timashev
·
RBC Capital
Edgewise Therapeutics price target raised to $66 from $52 at Raymond James
$66.00
(was $40.26)
Martin Auster
·
Raymond James
Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
$52.00
(was $40.26)
Laura Chico
·
Wedbush
Edgewise Therapeutics price target raised to $52 from $46 at Truist
$52.00
(was $37.30)
Truist Financial
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow"
$46.00
(was $29.67)
Martin Auster
·
Raymond James
Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI
$45.00
(was $29.66)
Cory Kasimov
·
Evercore ISI
Edgewise Therapeutics (EWTX) PT Raised to $25 at Stifel
$25.00
(was $29.83)
James Condulis
·
Stifel Nicolaus
Goldman Sachs assigns Neutral rating to Edgewise Therapeutics
$20.00
(was $16.59)
Goldman Sachs
Edgewise Therapeutics initiated with an Outperform at Scotiabank
$50.00
(was $28.01)
Scotiabank
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'
$50.00
(was $31.57)
Srikripa Devarakonda
·
Truist Financial
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
$51.00
(was $30.45)
Yasmeen Rahimi
·
Piper Sandler
Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital
$42.00
(was $29.50)
Leonid Timashev
·
RBC Capital
Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners
$42.00
(was $29.50)
Joseph Schwartz
·
Leerink Partners